Publications by authors named "Samir H Moussa"

Article Synopsis
  • - The study compared the effectiveness and safety of sulbactam-durlobactam versus colistin in treating carbapenem-resistant complex (CRABC) infections, focusing on both monomicrobial and polymicrobial cases using a combination with imipenem-cilastatin.
  • - Clinical outcomes showed that sulbactam-durlobactam performed similarly in both infection types, while colistin resulted in higher mortality for monomicrobial infections.
  • - The findings indicate that sulbactam-durlobactam could potentially improve treatment outcomes for polymicrobial CRABC infections, especially as it restored imipenem susceptibility in many cases, but more clinical evidence is needed for confirmation.
View Article and Find Full Text PDF
Article Synopsis
  • Sulbactam-durlobactam (SUL-DUR) is a new antibiotic designed to treat severe infections caused by antibiotic-resistant Acinetobacter baumannii (ABC), which is challenging to treat.
  • A phase 3 trial called ATTACK was conducted to compare SUL-DUR's effectiveness and safety against colistin, another treatment, in patients with serious infections from carbapenem-resistant strains.
  • Results indicated that SUL-DUR was as effective as colistin in reducing 28-day mortality rates, with better clinical and microbiological outcomes, while the report also included an analysis of the ABC isolates from trial participants and factors influencing SUL-DUR resistance.
View Article and Find Full Text PDF
Article Synopsis
  • The treatment of infections caused by carbapenem-resistant bacteria, particularly with emerging resistance to cefiderocol, is difficult and lacks clear solutions.
  • A documented case involved successfully treating a patient with pandrug-resistant bacteria using a compassionate use regimen of sulbactam-durlobactam antibiotics.
  • Longitudinal genomic analysis revealed the evolution of resistance and genetic mutations in the bacteria over time.
View Article and Find Full Text PDF
Article Synopsis
  • - ABC causes tough infections to treat because of antibiotic resistance, making treatment challenging.
  • - Sulbactam-durlobactam (SUL-DUR) is a new combination antibiotic aimed at fighting serious infections from multidrug-resistant strains of ABC.
  • - A recent study found that less than 2% of ABC isolates could resist SUL-DUR, and the main resistance factors involve specific enzyme mutations, while some common mutations do not lead to sulbactam resistance.
View Article and Find Full Text PDF

The development of new antibiotics to treat infections caused by drug-resistant Gram-negative pathogens is of paramount importance as antibiotic resistance continues to increase worldwide. Here we describe a strategy for the rational design of diazabicyclooctane inhibitors of penicillin-binding proteins from Gram-negative bacteria to overcome multiple mechanisms of resistance, including β-lactamase enzymes, stringent response and outer membrane permeation. Diazabicyclooctane inhibitors retain activity in the presence of β-lactamases, the primary resistance mechanism associated with β-lactam therapy in Gram-negative bacteria.

View Article and Find Full Text PDF
Article Synopsis
  • Durlobactam is a new β-lactamase inhibitor that works against a wide range of resistant bacteria, specifically targeting Ambler class A, C, and D enzymes.
  • Sulbactam, an older β-lactamase inhibitor, has limited effectiveness due to its vulnerability against many β-lactamases, but it also directly fights certain bacteria by disrupting their cell wall synthesis.
  • Combining sulbactam with durlobactam enhances sulbactam's effectiveness against multidrug-resistant infections, particularly those caused by carbapenem-resistant bacteria, and is currently being advanced for clinical use.
View Article and Find Full Text PDF

Mutations in KPC-2 and KPC-3 β-lactamase can confer resistance to the β-lactam/β-lactamase inhibitor antibacterial intravenous drug combination ceftazidime-avibactam, introduced in 2015. Avibactam was the first of the diazabicyclooctane class of non-β-lactam β-lactamase inhibitors to be approved for clinical use. The orally bioavailable prodrug ETX0282 of the diazabicyclooctane β-lactamase inhibitor ETX1317 is in clinical development in combination with the oral β-lactam prodrug cefpodoxime proxetil for use against complicated urinary tract infections.

View Article and Find Full Text PDF

UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase (LpxC), the zinc metalloenzyme catalyzing the first committed step of lipid A biosynthesis in Gram-negative bacteria, has been a target for antibacterial drug discovery for many years. All inhibitor chemotypes reaching an advanced preclinical stage and clinical phase 1 have contained terminal hydroxamic acid, and none have been successfully advanced due, in part, to safety concerns, including hemodynamic effects. We hypothesized that the safety of LpxC inhibitors could be improved by replacing the terminal hydroxamic acid with a different zinc-binding group.

View Article and Find Full Text PDF

Optimal phage propagation depends on the regulation of the lysis of the infected host cell. In T4 phage infection, lysis occurs when the holin protein (T) forms lesions in the host membrane. However, the lethal function of T can be blocked by an antiholin (RI) during lysis inhibition (LIN).

View Article and Find Full Text PDF

Multi-drug-resistant expressing a wide array of β-lactamases are emerging as a global health threat in both hospitals and communities. Although several intravenous drugs have recently been approved to address this need, there are no oral Gram-negative agents that are both safe and broadly effective against such pathogens. The lack of an effective oral agent is of concern for common infections which could otherwise be treated in the community but, due to antibiotic resistance, require hospitalization to allow for intravenous therapy.

View Article and Find Full Text PDF
Article Synopsis
  • - Sulbactam-durlobactam (SUL-DUR) is an antibiotic designed to effectively treat severe infections caused by complex organisms that are often resistant to multiple drugs, particularly multidrug-resistant strains.
  • - In testing against 1,722 clinical isolates from various regions, SUL-DUR showed significantly better antibacterial activity compared to sulbactam alone, and its efficacy was consistent across different types of infections and resistance patterns.
  • - Whole-genome sequencing of a small percentage of isolates with reduced effectiveness revealed specific resistance factors, indicating potential challenges in treating certain strains, but overall, SUL-DUR remains a powerful option against recent and diverse infections.
View Article and Find Full Text PDF

Multidrug-resistant (MDR) spp. poses a significant therapeutic challenge in part due to the presence of chromosomally encoded β-lactamases, including class C -derived cephalosporinases (ADC) and class D oxacillinases (OXA), as well as plasmid-mediated class A β-lactamases. Importantly, OXA-like β-lactamases represent a gap in the spectrum of inhibition by recently approved β-lactamase inhibitors such as avibactam and vaborbactam.

View Article and Find Full Text PDF

The susceptibility of small molecules to Gram-negative bacterial efflux is typically evaluated using an antibacterial activity-based efflux ratio, which is computed as the ratio of the antibacterial activity for a wild-type strain and its isogenic efflux mutant (typically lacking genes encoding major efflux pumps). The magnitude of the ratio is often used as an efflux index. However, early in drug discovery, hits with suboptimal physicochemical properties often lack whole cell inhibition against wild-type strains, which makes efflux ratios indeterminable.

View Article and Find Full Text PDF

The major Gram-negative gated efflux channel TolC has been extensively characterized in Escherichia coli but there is minimal information about Klebsiella pneumoniae TolC. Using an arabinose-inducible plasmid-based expression system, we show that the K. pneumoniae TolC complements the efflux defect in an E.

View Article and Find Full Text PDF

OmpA is a conserved, abundantly expressed outer membrane porin in Acinetobacter baumannii whose presumed role in antibiotic permeation has not been clearly demonstrated. In this report, we use a titratable heterologous expression system to express OmpA in isolation and demonstrate selective passage of small molecule antibiotics through OmpA. ETX2514, a recently discovered broad-spectrum β-lactamase inhibitor, in combination with sulbactam, is currently in clinical testing for the treatment of drug-resistant A.

View Article and Find Full Text PDF

The novel diazabicyclooctenone ETX2514 is a potent, broad-spectrum serine β-lactamase inhibitor that restores sulbactam activity against resistant The frequency of spontaneous resistance to sulbactam-ETX2514 in clinical isolates was found to be 7.6 × 10 to <9.0 × 10 at 4× MIC and mapped to residues near the active site of penicillin binding protein 3 (PBP3).

View Article and Find Full Text PDF

Multidrug-resistant (MDR) bacterial infections are a serious threat to public health. Among the most alarming resistance trends is the rapid rise in the number and diversity of β-lactamases, enzymes that inactivate β-lactams, a class of antibiotics that has been a therapeutic mainstay for decades. Although several new β-lactamase inhibitors have been approved or are in clinical trials, their spectra of activity do not address MDR pathogens such as Acinetobacter baumannii.

View Article and Find Full Text PDF

The majority of bacterial proteins are dispensable for growth in the laboratory but nevertheless have important physiological roles. There are no systematic approaches to identify cell-permeable small-molecule inhibitors of these proteins. We demonstrate a strategy to identify such inhibitors that exploits synthetic lethal relationships both for small-molecule discovery and for target identification.

View Article and Find Full Text PDF

Background: Staphylococcus aureus readily develops resistance to antibiotics and achieving effective therapies to overcome resistance requires in-depth understanding of S. aureus biology. High throughput, parallel-sequencing methods for analyzing transposon mutant libraries have the potential to revolutionize studies of S.

View Article and Find Full Text PDF

Staphylococcus aureus contains two distinct teichoic acid (TA) polymers, lipoteichoic acid (LTA) and wall teichoic acid (WTA), which are proposed to play redundant roles in regulating cell division. To gain insight into the underlying biology of S. aureus TAs, we used a small molecule inhibitor to screen a highly saturated transposon library for cellular factors that become essential when WTA is depleted.

View Article and Find Full Text PDF

t is the holin gene for coliphage T4, encoding a 218-amino-acid (aa) protein essential for the inner membrane hole formation that initiates lysis and terminates the phage infection cycle. T is predicted to be an integral membrane protein that adopts an N(in)-C(out) topology with a single transmembrane domain (TMD). This holin topology is different from those of the well-studied holins S105 (3 TMDs; N(out)-C(in)) of the coliphage lambda and S68 (2 TMDs; N(in)-C(in)) of the lambdoid phage 21.

View Article and Find Full Text PDF

At a programmed time in phage infection cycles, canonical holins suddenly trigger to cause lethal damage to the cytoplasmic membrane, resulting in the cessation of respiration and the non-specific release of pre-folded, fully active endolysins to the periplasm. For the paradigm holin S105 of lambda, triggering is correlated with the formation of micron-scale membrane holes, visible as interruptions in the bilayer in cryo-electron microscopic images and tomographic reconstructions. Here we report that the size distribution of the holes is stable for long periods after triggering.

View Article and Find Full Text PDF

Genetic studies have established that lysis inhibition in bacteriophage T4 infections occurs when the RI antiholin inhibits the lethal hole-forming function of the T holin. The T-holin is composed of a single N-terminal transmembrane domain and a ~20 kDa periplasmic domain. It accumulates harmlessly throughout the bacteriophage infection cycle until suddenly causing permeabilization of the inner membrane, thereby initiating lysis.

View Article and Find Full Text PDF

The mechanism of Bax/Bak-dependent mitochondrial outer membrane permeabilization (MOMP), a central apoptotic event primarily controlled by the Bcl-2 family proteins, remains not well understood. Here, we express active Bax/Bak in bacteria, the putative origin of mitochondria, and examine their functional similarities to the λ bacteriophage (λ) holin. As critical effectors for bacterial lysis, holin oligomers form membrane lesions, through which endolysin, a muralytic enzyme, escapes the cytoplasm to attack the cell wall at the end of the infection cycle.

View Article and Find Full Text PDF

The field of bacterial source tracking (BST) has been rapidly evolving to meet the demands of water pollution analysis, specifically the contamination of waterways and drinking water reservoirs by point source and nonpoint source pollution. The goal of the current study was to create a BST library based on carbon-utilization patterns (CUP) for predicting sources of E. coli in a watershed, to compare this library to an antibiotic-resistance analysis (ARA) library previously published for the same isolates, and to determine the efficacy of using a composite dataset which combines data from both datasets into a single library for predicting the source of unknown isolates.

View Article and Find Full Text PDF